Cronos Group (NASDAQ:CRON) Stock Rating Raised to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Cronos Group (NASDAQ:CRON) from a hold rating to a buy rating in a report released on Saturday morning,Wall Street Zen reports.

A number of other equities analysts have also commented on the stock. TD Securities restated a “buy” rating on shares of Cronos Group in a research report on Monday, September 28th. Zacks Research raised shares of Cronos Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 22nd. Finally, Weiss Ratings upgraded shares of Cronos Group from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $2.30.

Cronos Group Stock Performance

Shares of NASDAQ:CRON opened at $3.61 on Friday. Cronos Group has a 52 week low of $2.28 and a 52 week high of $3.91. The company’s fifty day moving average is $3.31 and its 200-day moving average is $2.88. The company has a market capitalization of $1.32 billion, a PE ratio of 21.24 and a beta of 0.96.

Cronos Group (NASDAQ:CRON) last posted its earnings results on Thursday, November 5th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.01. The business had revenue of $63.45 million for the quarter, compared to analyst estimates of $51.15 million. Cronos Group had a net margin of 28.04% and a return on equity of 2.56%. On average, analysts forecast that Cronos Group will post 0.12 EPS for the current year.

Institutional Investors Weigh In On Cronos Group

Large investors have recently modified their holdings of the business. Pure Financial Advisors LLC acquired a new stake in shares of Cronos Group during the second quarter worth about $28,000. OneDigital Investment Advisors LLC acquired a new position in shares of Cronos Group in the 2nd quarter valued at approximately $29,000. Two Sigma Securities LLC acquired a new position in shares of Cronos Group in the 2nd quarter valued at approximately $34,000. Concurrent Investment Advisors LLC increased its stake in Cronos Group by 69.0% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 19,623 shares of the company’s stock worth $55,000 after purchasing an additional 8,009 shares in the last quarter. Finally, Amundi bought a new stake in Cronos Group during the 1st quarter worth approximately $54,000. 8.71% of the stock is currently owned by institutional investors.

Trending Headlines about Cronos Group

Here are the key news stories impacting Cronos Group this week:

• Positive Sentiment: Q3 net revenue rose 73% year over year on an organic, constant-currency basis, with the company reporting record net revenue, gross profit and adjusted EBITDA. Revenue of $63.45 million and earnings of $0.04 per share also exceeded analyst estimates of $51.15 million and $0.03, respectively. Cronos Group Reports 2026 Third Quarter Results
• Positive Sentiment: Growth was broad-based: Cronos posted record Canadian sales, a record quarter in Germany, and its 11th consecutive quarter of record net revenue in Israel. Its Spinach brand retained the top position in Canadian vapes and edibles, while the Canatolar acquisition expands its European reach. Q3 2026 Earnings Call Highlights
• Neutral Sentiment: The company said it reduced its share count, which can support per-share results, though the available reports do not quantify the effect. Cronos Group Reports 2026 Third Quarter Results
• Negative Sentiment: Despite beating estimates, Q3 earnings of $0.04 per share were below the $0.07 reported a year earlier. A separate valuation discussion also notes that the stock’s 93% three-year gain puts more focus on whether current earnings justify its valuation. Cronos Group Stock Looks Hard To Call Following Its 93% Run

Cronos Group Company Profile

Cronos Group Inc is a Canadian cannabinoid company focused on developing, producing and commercializing cannabis and cannabis-derived consumer products. The company serves adult-use and medical cannabis markets through a portfolio of brands and sells products such as dried flower, pre-rolls, vaporizers, edibles, oils and other cannabis formats, subject to applicable regulations.

Its brand portfolio has included Spinach, which is positioned primarily in the adult-use cannabis market, as well as Lord Jones and PEACE NATURALS.